On November 17, 2026, the Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting:
- one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or
- two or more prior ALK TKIs and platinum-based chemotherapy.
